Amarin Corporation PLC Announces Additional Publication of MARINE Phase 3 Clinical Trial Results in the Journal of Clinical Lipidology

Published: Aug 29, 2012

BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 28, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that additional data from its pivotal MARINE Phase 3 clinical trial are now available electronically through the Journal of Clinical Lipidology and are expected to be published in a future print issue of the journal before the end of 2012.

Back to news